Last reviewed · How we verify
Imuneks 10mg
Imuneks 10mg is a Small molecule drug developed by Imuneks Farma ilac San. Tic. A.S.. It is currently FDA-approved. Also known as: micronized Beta-1,3/1,6-D-glucan.
Imuneks 10mg, marketed by Imuneks Farma ilac San. Tic. A.S., is a pharmaceutical product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by its current marketing status. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Imuneks 10mg |
|---|---|
| Also known as | micronized Beta-1,3/1,6-D-glucan |
| Sponsor | Imuneks Farma ilac San. Tic. A.S. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imuneks 10mg CI brief — competitive landscape report
- Imuneks 10mg updates RSS · CI watch RSS
- Imuneks Farma ilac San. Tic. A.S. portfolio CI
Frequently asked questions about Imuneks 10mg
What is Imuneks 10mg?
Who makes Imuneks 10mg?
Is Imuneks 10mg also known as anything else?
What development phase is Imuneks 10mg in?
Related
- Manufacturer: Imuneks Farma ilac San. Tic. A.S. — full pipeline
- Also known as: micronized Beta-1,3/1,6-D-glucan
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing